1. Аркадьева Г.В., Радзевич А.Э. Длительная терапия варфарином у больных с мерцательной аритмией без поражения клапанов сердца с целью профилактики тромбоэмболических осложнений. Рос. кардиол. журн. 2005; 6: 50–6.
2. Сердечная Е.В., Татарский Б.А., Истомина Т.А. Эпидемиология фибрилляции предсердий. Экология человека. 2009; 11: 48–54.
3. Apostolakis S, Lane DA, Guo Y et al. Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores in anticoagulated patients with atrial fibrillation: The AMADEUS study. JACC 2012; 60: 861–7.
4. Boriani G, Botto GL, Padeletti L et al. Italian AT-500 Registry Investigators. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 2011; 42: 1768–70.
5. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51.
6. Connolly SJ, Eikelboom J, Joyner C et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–17.
7. Friberg J, Scharling H, Gadsboll N et al. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004; 94: 889–94.
8. Friberg J, Scharling H, Gadsboll N et al. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol 2003; 92: 1419–23.
9. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for is-chaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2012; 33: 1500–10.
10. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal 
atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: 967–75.
11. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5.
12. Hart RG, Pearce LA, Aguilar MI. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
13. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949–53.
14. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295–304.
15. Jahangir A, Lee V, Friedman PA et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 2007; 115: 3050–6.
16. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803–17.
17. Lane DA, Lip GYH. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation. Circulation 2012; 126: 860–5.
18. Lin LY, Lee CH, Yu CC et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation – a nationwide database analysis. Atherosclerosis 2011; 217: 292–5.
19. Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost 2011; 9 (Suppl. 1): 344–51.
20. Michelena HI, Ezekowitz MD. Atrial fibrillation: are there gender differences? J Gend Specif Med 2000; 3: 44–9.
21. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119–25.
22. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534–9.
23. Olesen JB, Lip GY, Lindhardsen J et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a «real world» nationwide cohort study. Thromb Haemost 2011; 106: 739–49.
24. Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J 2011; 342.
25. Patel MR, Mahaffey KW, Garg J et al for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91.
26. Psaty BM, Manolio TA, Kuller LH et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455–61.
27. Coyne KS, Grandy S, Paramore C et al. Resource use and costs associated with atrial fibrillation in the US. Circulation 2004; 110 (Suppl. III): 826–32.
28. Roldan V, Marin F, Manzaro-Fernandez S et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a ’real world’ anticoagulated atrial fibrillation population. Chest 2012; http://dx.doi.org/10.1378/chest.12-0608»doi:10.1378/chest.12-0608
29. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038–45.
30. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516–21.
31. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359–64.
32. Stroke in AF working group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69: 546–54.
33. Flaherty ML, Kissela B, Woo D et al. The increasing incidence of anticoagulant-associated intracerbral hemorrhage. Neurology 2007; 68: 116–21.
34. Turtzo LC, McCullough LD. Sex Differences in Stroke. Cerebrovasc Dis 2008; 26: 462–74.
35. Van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation. Stroke 2009; 40: 1410–6.
36. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–91.
37. Wolf PA, Mitchell JB, Baker CS et al. Impact of Atrial Fibrillation on Mortality, Stroke, and Medical Costs. Arch Intern Med 1998; 158: 229–34.

В.А.Сергеева, С.В.Майорова

Кафедра госпитальной терапии ГБОУ ВПО Саратовский ГМУ им. В.И.Разумовского Минздрава России